Reaction
Follicular Lymphoma reporting signals
As of the last recalculation, Follicular Lymphoma appears in 842 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is OBINUTUZUMAB (PRR 334.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Obinutuzumab | 176 | 334.1 | 337.7 |
| Bendamustine Hcl | 121 | 225.1 | 226.9 |
| Polatuzumab Vedotin | 45 | 120.4 | 120.9 |
| Bendamustine Hydrochloride | 47 | 102.7 | 103.1 |
| Doxorubicin | 233 | 89.0 | 89.2 |
| Rituximab | 383 | 81.3 | 81.5 |
| Vincristine Sulfate | 77 | 71.4 | 71.6 |
| Doxorubicin Hydrochloride | 82 | 68.7 | 68.8 |
| Ifosfamide | 53 | 65.0 | 65.2 |
| Cyclophosphamide Injection, Solution | 256 | 50.9 | 51.0 |
| Cyclophosphamide | 256 | 50.9 | 51.0 |
| Cyclophosphamide For Injection | 256 | 50.9 | 51.0 |
| Axicabtagene Ciloleucel | 18 | 46.1 | 46.1 |
| Gemcitabine | 51 | 34.0 | 34.0 |
| Gemcitabine Hydrochloride | 64 | 32.2 | 32.2 |
| Cytarabine | 71 | 31.8 | 31.8 |
| Etoposide | 80 | 29.6 | 29.6 |
| Melphalan | 22 | 24.5 | 24.5 |
| Mesna Injection | 8 | 24.2 | 24.2 |
| Cisplatin | 70 | 24.1 | 24.1 |
| Mesna | 8 | 23.7 | 23.7 |
| Melphalan Hydrochloride | 22 | 22.2 | 22.3 |
| Oxaliplatin | 40 | 13.9 | 14.0 |
| Carboplatin | 51 | 10.5 | 10.5 |
| Venetoclax | 21 | 8.6 | 8.6 |
| Acalabrutinib | 4 | 8.2 | 8.2 |
| Lenalidomide | 114 | 7.6 | 7.6 |
| Peginterferon Beta-1A | 3 | 5.7 | 5.7 |